Association of GUCY2C expression in lymph nodes with time to recurrence and disease- free survival in pN0 colorectal cancer

JAMA

Volumn 301, Issue 7, 2009, Pages 745-752

  Waldman, Scott A ^a   Hyslop, Terry ^a   Schulz, Stephanie ^a   Barkun, Alan ^b   Nielsen, Karl ^a   Haaf, Janis ^a   Bonaccorso, Christine ^a   Li, Yanyan ^a   Weinberg, David S ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; FLUOROURACIL; GUANYLYL CYCLASE 2C; MESSENGER RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ENTEROTOXIN RECEPTOR; GUANYLATE CYCLASE; RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECURRENT CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNITED STATES; CANCER STAGING; COLORECTAL TUMOR; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; OBSERVATION; PROPORTIONAL HAZARDS MODEL; TUMOR RECURRENCE;

AGED; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GUANYLATE CYCLASE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OBSERVATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, PEPTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 60749102639     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.141     Document Type: Article

References (42)

1. Iddings D, Ahmad A, Elashoff D, Bilchik A. The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta-analysis. Ann Surg Oncol. 2006;13(11):1386-1392.
2. Nicastri DG, Doucette JT, Godfrey TE, Hughes SJ. Is occult lymph node disease in colorectal cancer patients clinically significant? a review of the relevant literature. J Mol Diagn. 2007;9(5):563-571.
3. Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004; 54(6):295-308.
4. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57(1):43-66.
5. Andre T, Boni C, Mounedji-Boudiaf L, et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343-2351.
6. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol. 1999;17(5):1349-1355.
7. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352(5):476- 487.
8. Quasar Collaborative Group; Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020-2029.
9. Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment ofcolorectal cancer. CA Cancer J Clin. 2007;57(3):168-185.
10. Li P, Schulz S, Bombonati A, et al. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology. 2007;133(2):599-607.
11. Pitari GM, Li P, Lin JE, et al. The paracrine hormone hypothesis of colorectal cancer. Clin Pharmacol Ther. 2007;82(4):441-447.
12. Birbe R, Palazzo JP, Walters R, Weinberg D, Schulz S, Waldman SA. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol. 2005;36 (2):170-179.
13. SchulzS, Hyslop T, HaafJ, etal. Avalidated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin Cancer Res. 2006;12(15):4545-4552.
14. Witek ME, Nielsen K, Walters R, et al. The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clin Cancer Res. 2005;11(24 pt 1):8549-8556.
15. Cagir B, Gelmann A, Park J, et al. Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Ann Intern Med. 1999; 131(11):805-812.
16. Carrithers SL, Barber MT, Biswas S, et al. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc Natl Acad Sci USA. 1996;93(25):14827-14832.
17. Frick GS, Pitari GM, Weinberg DS, Hyslop T, Schulz S, Waldman SA. Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev Mol Diagn. 2005; 5(5):701-713.
18. Moertel CG, O'Fallon JR, Go VL, O'Connell MJ, Thynne GS. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer. 1986;58(3):603-610.
19. ChervonevaI, Li Y, IglewiczB, Waldman S, Hyslop T. Relativequantification based on logisticmodelsfor individual polymerase chain reactions. StatMed. 2007; 26(30):5596-5611.
20. Punt CJ, Buyse M, Kohne CH, et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst. 2007;99(13):998- 1003.
21. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857-872.
22. Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002;359(9318):1686- 1689.
23. Greene FL. AJCC CancerStagingManual.6th ed. New York, NY: Springer; 2002.
24. Hosmer D, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York, NY: Wiley; 1999.
25. Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003; 21(15):2912-2919.
26. Swanson RS, Compton CC, Stewart AK, Bland KI. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol. 2003;10(1):65-71.
27. Bilchik AJ, Hoon DS, Saha S, et al. Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg. 2007; 246(4):568-575.
28. Hitchcock CL, Sampsel J, Young DC, Martin EW Jr, Arnold MW. Limitations with light microscopy in the detection of colorectal cancer cells. Dis Colon Rectum. 1999;42(8):1046-1052.
29. Ratto C, Sofo L, Ippoliti M, et al. Accurate lymphnode detection in colorectal specimens resected for cancer is of prognostic significance. Dis Colon Rectum. 1999;42(2):143-154.
30. Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. Nat Protocols. 2006; 1(3):1559-1582.
31. Brown HG, LuckasevicTM, Medich DS, Celebrezze JP, Jones SM. Efficacy ofmanual dissection of lymph nodes in colon cancer resections. Mod Pathol. 2004; 17(4):402-406.
32. Herrera-Ornelas L, Justiniano J, Castillo N, Petrelli NJ, Stulc JP, Mittelman A. Metastases in small lymph nodes from colon cancer. Arch Surg. 1987;122 (11):1253-1256.
33. Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408-3419.
34. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22(10):1797-1806.
35. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol. 2004; 22(16):3395-3407.
36. Waldman SA, Christensen NB, Moore JE, Terzic A. Clinical pharmacology: the science oftherapeutics. Clin Pharmacol Ther. 2007;81(1):3-6.
37. Waldman SA, TerzicMR, TerzicA. Molecular medicine hones therapeutic arts to science. Clin Pharmacol Ther. 2007;82(4):343-347.
38. Croner RS, Peters A, Brueckl WM, et al. Microarray versus conventional prediction of lymph node metastasis in colorectal carcinoma. Cancer. 2005; 104(2):395-404.
39. Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet. 2006;38(5):540-549.
40. Jen J, Kim H, Piantadosi S, etal. Alleliclossofchromosome 18q and prognosis in colorectal cancer. N Engl J Med. 994;331(4):213-221.
41. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node- negative breast cancer. N Engl J Med. 2004;351 (27):2817-2826.
42. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol. 2004; 22(9):1564-1571.